HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating for Ventyx Biosciences (NASDAQ:VTYX) and maintained a price target of $6.
June 06, 2024 | 10:57 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Neutral rating for Ventyx Biosciences and maintained a price target of $6.
The reiteration of a Neutral rating and maintenance of the $6 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100